Welcome : Guest

XOMA Corporation (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about XOMA Corporation, which is principally a Development Stage Biotechnology Company. Illustrated with 47 tables, the report showcases the company's sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-65766
Price: $2350
Company Type: Public
Pages: 49
Date: November 2016
Market Data Tables: 47

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: Xoma Corporation's Sales by Geographic Region Worldwide (2015) in Percentage for United States, Europe......2
Monoclonal Antibodies......4
Table 2: Monoclonal Antibodies Market by Drugs Worldwide (2015) - Percentage Share Breakdown by Value for Avastin, Crestor, Enbrel, Humira, Lantus, Remicade and Others......4
Table 3: Biotechnology Drugs by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Cell Therapy, Gene Therapy, Monoclonal Antibodies (MAB), Recombinant Hormones and Proteins, Vaccines, and Others......5
Table 4: Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Biologics, Monoclonal Antibodies and Other Classes......6
Table 5: Therapeutic Development Market by Product Worldwide (2015) - Percentage Share Breakdown by Volume for Cell Therapy, Monoclonal Antibodies, Vaccines and Others......7
Table 6: Antiviral Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others......8
Table 7: Therapeutic Biologics Market by Type in China (2015) - Percentage Share Breakdown by Value for Erythropoietin (EPO), Granulocyte Colony-Stimulating Factor (GCSF), Insulin, Interferon, Interleukin, Monoclonal Antibodies (MAb), Nerve GF, Somatropin, and Others......9
Table 8: Proteins Market by Segment in China (2015) - Percentage Share Breakdown by Value for Erythropoietin (EPO), Granulocyte Colony Stimulating Factor (GCSF), Insulin, Interferon, Interleukin, Monoclonal Antibody (MAb), Nerve Growth Factor (NGF), and Somatropin......10
Diabetes Market......11
Table 9: Diabetes Market by Region Worldwide (2015) - Percentage Share Breakdown for Africa, Europe, Middle East & North Africa, North America & Caribbean, Southeast Asia, and Western Pacific......11
Table 10: Diabetes Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Insulin Type‐1 Diabetes, Insulin Type‐2 Diabetes, Dipeptidyl Peptidase 4, (DPP4), Glucagon-like Peptide-1 (GLP‐1), Dipeptidyl Peptidase 4, (DPP4) + Biguanide, and Others* (includes Sodium-Glucose Co-Transporter-2 (SGLT2), Biguanide, Sulfonylurea, Alpha-Glucosidase Inhibitors, Peroxisome Proliferator-Activated Receptor (PPAR)......12
Table 11: Diabetes Care Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Human Insulins, Modern Insulins, Victoza, and Others......13
Table 12: Type-II Diabetes Treatments Market Worldwide (2015-2020) in US$ Million......14
Table 13: Type II Diabetes Market by Treatment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-IV Inhibitors, GLP-1 Agonists, SGLT-2 Inhibitors and Thiazolidinediones......15
Table 14: Type II Diabetes Market by Insulin Treatment Worldwide (2015) - Percentage Share Breakdown by Value for Diet and Exercise Only, Insulin and Orals and Insulin Only......16
Table 15: Diabetes Healthcare Market by Category in the US (2015) - Percentage Share Breakdown by Value for Anti -Diabetic Agents & Supplies, Doctor Office Visits, Hospital Care, Nursing/Residential Facility Stays, Prescription Medication, and Others......17
Table 16: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown for Insulin Pumps, and Multiple Daily Injections......18
Table 17: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown by Value for Type 1, and Type 2......19
Table 18: No. of Diabetes Patients by Medication in the US (2015) - Percentage Share Breakdown for Insulin and Oral Medication, Insulin Only, No Medication, and Oral Medication Only......20
Diabetes Drugs......21
Table 19: Diabetes Drug Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-4 Inhibitor, GK Activator, GLP-1 Agonist, GPCR Agonist, IL- Receptor Antagonist, Insulin Analogue, PPAR Agonist, SGLT-2 Inhibitor, and Others......21
Table 20: Diabetes/Metabolic Drugs Market by Category Worldwide (2015) - Percentage Breakdown by Value Sales for DPP-IV Inhibitors, Glitazones, GLP-1 Analogs, Insulins, Sulfonylureas, and Others......22
Table 21: Anti-Diabetic Drug Market by Treatment Class Worldwide (2015) - Percentage Share Breakdown by Value for Diet & Exercise, Incretion, Insulin and Oral Anti-Diabetic......23
Table 22: Antidiabetes Molecules Market by Drug Worldwide (2015) - Percentage Share Breakdown by Value for Metformin, Sulfonylureas, Thiazolidin Ediones and Others......24
Table 23: Anti-Diabetic Drugs Market in China (2015-2020) in RMB Million......25
Table 24: Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glinide, Insulin, Sulfonylureas, α-glucosidase Inhibitor, and Others......26
Table 25: Anti-Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Insulin Drugs and Non-Insulin Drugs......27
Table 26: Diabetes Drugs Market by Product Category in China (2015) - Percentage Share Breakdown by Value for Acarbose, Insulin, Melbine, and Other Diabetes Drugs......28
Table 27: Diabetic Drugs Market by Category in the US (2015) - Percentage Share Breakdown by Value for DPP-IV & SGLT-2, GLP-1, Insulins, and Others......29
Table 28: Diabetic Drugs Market by Non-Insulin Therapy in the US (2015) - Percentage Share Breakdown by Volume for Biguanides, DPP-4 Inhibitor, Human GLP-1 Analogs, SGLT-2 Inhibitor, Sulfonylureas, and Others......30
Table 29: Oral Diabetes Medicine Market in the US (2015) - Percentage Share Breakdown by Value Sales for Dipeptidyl Peptidase-4 (DPP4), Metformin, Sulfonylureas, and Others......31
Non-Insulin Anti-Diabetic Drugs......32
Table 30: Non-Insulin Anti-Diabetic Drugs Market by Product in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glucosidase Inhibitors, Nateglinide, Sulfonylurea and Others......32
Diabetic Macular Edema (DME)......33
Table 31: Diabetic Macular Edema (DME) Market by Drug Treatment Worldwide (2015) - Percentage Share Breakdown by Volume for Avastin, Laser Photocoagulation, Lucentis 0.3 mg, Steroids and Others......33
Table 32: Diabetic Macular Edema (DME) Anti Vascular Endothelial Growth Factor (VEGF) Market by Segment in the US (2015) - Percentage Share Breakdown by Volume for Avastin, Lucentis and Others......34
DPP-4 Inhibitors......35
Table 33: DPP-4 Inhibitors Market by Product Category Worldwide (2015) - Percentage Share Breakdown by Value for Galvus & Galvumet (Novartis), Januvia & Janumet (MRK), Nesina & Kezano (Takeda), Onglyza & Kombiglyze (AZN/BMY) and Tradjenta & Jentadueto (BI/Lilly)......35
Table 34: DPP-4 Inhibitors Market in China (2015-2020) in RMB Million......36
Table 35: DPP-4 type Diabetes Drugs Market in Japan (2015) in Yen Million......37
Table 36: DPP-4 Inhibitors (Fixed Dose) Market by Product Category in Korea (2015) - Percentage Share Breakdown by Value for Galvusmet, Janumet, Janumet XR, Kombiglyze, Trajenta Duo and Zemimet......38
Table 37: DPP-4 Inhibitors (Non-fixed Dose) Market by Product Category in Korea (2015) - Percentage Share Breakdown by Value for Januvia, Nesina, Tradjenta, Zemiglo, and Others......39
Table 38: DPP-4 Inhibitors Market by Prescription in the US (2015) - Percentage Share Breakdown by Volume for Janumet (Sitagliptin + Metformin), Januvia (Sitagliptin), Kombiglyze XR (Saxagliptin + Metformin), Onglyza (Saxagliptin), and Others......40
Table 39: DPP-4 Inhibitors Market in the US (2015) in No. of Prescriptions......41
Diabetes Drugs......42
Table 40: Market Shares of Leading Diabetes Care Companies Worldwide (2014) - Percentage Breakdown by Value Sales for Bristol-Myers Squibb (Incl Amylin), Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi S.A. and Others......42
Table 41: Market Shares of Leading Diabetes Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., and Others......43
Table 42: Market Shares of Leading Anti-Diabetic Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Abbott Healthcare Pvt Ltd., Biocon Limited, Lupin Pharmaceuticals, Inc., MSD Pharmaceuticals Private Limited, Sanofi-Aventis Groupe, Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., and Others......44
DPP-4 Inhibitors......45
Table 43: Market Shares of Leading DPP-4 Inhibitors Manufacturers by Value Sales Worldwide (2015) - Percentage Share Breakdown for Merck & Co., Inc. (Januvia/Janumet), Novartis AG (Galvus/Galvumet) and Takeda Pharmaceutical Co., Ltd. (Nesina/Kezano), and Others......45
Table 44: Market Shares of Leading DPP-4 Inhibitors for Treatment of Diabetes in Japan (2015) - Percentage Share Breakdown by Value for Equa, Glactiv, Januvia, Nesina, and Others......46
Table 45: Market Shares of Leading DPP-4 Drug Brands in China (2015) - Percentage Share Breakdown by Value for Galvus, Januvia, Onglyza, and Others......47
Metformin......48
Table 46: Market Shares of Leading Metformin Suppliers in India (2015) - Percentage Share Breakdown by Value for Harman Finochem Ltd., USV Pharmaceuticals Ltd., Wanbury Limited and Others......48
Table 47: Xoma Corporation’s Sales by Geographic Region Worldwide (2013-2014) in Percentage for United States, Europe and Asia-Pacific......49